Richard Chin, MD
Richard Chin is a Harvard-trained physician and a former Rhodes Scholar with a track record of almost a dozen drug approvals and over 50 INDs. Drugs Richard developed, including Lucentis®, Xolair®, Tysabri®, and Rituxan® for immune diseases, have current aggregate sales of well over $10 billion per year.
Previously, Richard was Head of Clinical Research for the Biotherapeutics Unit at Genentech where he oversaw all of Genentech’s drug development programs except oncology products; Senior VP of Global Development at Elan; CEO of Oxigene, a NASDAQ-listed biotechnology company; and CEO of OneWorld Health, a Gates Foundation-funded nonprofit developing drugs for impoverished patients in developing countries. Richard was named by BusinessWeek in 2006 as one of 99 youngest public company CEOs in the United States. He has authored several major textbooks on clinical development and teaches drug development at UCSF.
Jay Peterson has over 15 years of experience in biopharmaceutical contract manufacturing encompassing process development scale-up and production scale biologics from both mammalian and microbial hosts. Prior to joining KindredBio, he led upstream production, fill finish and manufacturing compliance teams at Cytovance Biologics. With expertise in production planning, equipment validation, compliance, program management, and training development for cGMP operations, Jay is strongly positioned to direct biomanufacturing at KindredBio’s state-of-the-art Elwood, KS facility.
Russell Radefeld is an accomplished technology leader with over 20 years of experience in the animal health and life sciences industry. With a strong business sense, a deep knowledge of IT, and comprehensive digital marketing expertise, Russell has helped drive initiatives at KindredBio across many fronts during his time in the organization. Prior to KindredBio, Russell managed the digital platform at one of the largest specialty pet food manufacturers in the world, helping to deliver success throughout the business, primarily focused on the technology side of marketing and building out industry leading social media marketing initiatives. Throughout his early career in a Fortune 250 company, he helped drive many groundbreaking programs such as ecommerce, social media, ERP implementation, systems integration, and delivering world class digital marketing.
Hangjun Zhan, PhD
Dr. Zhan is a highly regarded protein biochemist and biophysicist with 20 years of drug discovery experience in the biotech industry. He joined KindredBio in February 2014 to lead biologics research. Previously, Dr. Zhan served as an executive member at Aragen Biosciences and led their protein sciences group. Prior to that, he established and headed up the Protein Biochemistry Group at Exelixis, including protein expression, fermentation/bioproduction, protein purification/biophysics, and proteomics. His team’s work led to more than 20 drug candidates. He has also previously served as group leader of Protein Chemistry at Axys Biopharmaceuticals (Celera) where he managed a fermentation group and a protein biochemistry group. Dr. Zhan completed his post-doctoral training in Dr. John Collier’s lab at Harvard Medical School; there, he applied in-depth biophysics to elucidate dynamic protein structural changes in solution and in membrane. While earning his Ph.D. from the University of Washington, he discovered a novel chemical-signaling molecule involved in bacterial invasion.